Trillium Therapeutics USA, LLC
$1.3M 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Vilex LLC
Vilex LLC reported $1,348,974.10 across General Payments, Research, and Ownership to 1,040 physicians and teaching hospitals across 1,093 transactions.
- $1.3M
- All-tracks total
- 1,093
- Transactions
- 1,040
- Recipients
- −$6.8K
- General Payments vs PY2023
Vilex LLC reported $1,348,974.10 across all CMS Open Payments tracks (General + Research + Ownership) to 1,040 physicians and teaching hospitals in Program Year 2024 - ranking #545 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,140,154.85, averaging $1.3K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer vilex-llc Vilex LLC
$1.3M · #545/1,925 · 0.0% industry · PY2024
- TOT $1.3M
- RANK #545
- SHARE 0.0%
- TXN 1,093
- RCP 1,040
- CAT 4
- GEN $1.1M
- ΔGEN −$6.8K
- TOP1 8.8%
- PY 2024
Volume peers
Nearest volume peer: Trillium Therapeutics USA, LLC ($1.3M)
Vilex LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Vilex LLC's CMS-reported General Payments decreased by $6.8K (−0.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: VILEX LLCPY2023: VILEX LLCPY2024: VILEX LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,146,908.46
- PY2024
- $1,140,154.85
What the Data Shows for Vilex LLC
Rank #545 of 1,925 companies in CMS Open Payments for 2024 belongs to Vilex LLC, which reported $1,348,974.10 across 1,093 transactions to 1,040 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $1.2K per transaction and $1.3K per recipient.
Of the 4 general-payment categories charted below, "Royalty or License" is the largest at $514.9K across 184 transactions, 45.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Vilex LLC's largest category was "Royalty or License" at $514.9K - 45.2% of General Payments.
Vilex LLC reports 4 general-payment categories - the top three are Royalty or License (45.2%), Travel and Lodging (33.7%), and Consulting Fee (19.8%). The remaining 1 category make up 1.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Vilex LLC divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $514.9K | 184 | 45.2% |
| Travel and Lodging | $384.0K | 480 | 33.7% |
| Consulting Fee | $226.1K | 125 | 19.8% |
| Food and Beverage | $15.2K | 251 | 1.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $395,632.25 (34.7%) of $1,140,154.85 in this company's General Payments records across 133 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Vilex LLC
The five named recipients with the highest reported General Payments from this company
- 1
Jesse Doty
$100,164.34 across 67 reported transactions
- 2
Spencer Monaco
$85,322.27 across 50 reported transactions
- 3
Jeffrey Loveland
$76,758.77 across 17 reported transactions
- 4
James Cottom
$74,696.07 across 54 reported transactions
- 5
Peter Blume
$58,690.80 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Vilex LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Vilex LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Vilex LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Biofrontera Bioscience GmbH
$1.3M 0 recipients
Compare payment profiles
Vericel Corporation
$1.3M 3,314 recipients
Compare payment profiles
Telix Pharmaceuticals
$1.3M 2,920 recipients
Compare payment profiles
Leadiant Biosciences, Inc.
$1.3M 65 recipients
Compare payment profiles
Surmodics, Inc.
$1.3M 2,433 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.